AMENDED AND RESTATED SUBSCRIPTION AGREEMENTSubscription Agreement • July 9th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Amended and Restated Subscription Agreement (this “Agreement”) is made and entered into as of July 3, 2024 (the “Effective Date”) by and among Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), each of the purchasers listed on the signature pages hereto, severally and not jointly (each a “Purchaser” and together, the “Purchasers”), and each of the purchasers of warrants listed on the signature pages hereto as updated from time to time, severally and not jointly (each an “Employee Warrant Purchaser” and together, the “Employee Warrant Purchasers”). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 8 hereof.
RE: Subscription Agreement – Purchase PriceSubscription Agreement • July 9th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
Reference is made to that certain Subscription Agreement, dated April 3, 2024 (the “Subscription Agreement”), by and among Oruka Therapeutics, Inc. (the “Company”) each of the purchasers listed on the signature pages thereto. Capitalized terms used but not defined in this letter shall have the meanings given to such terms in the Subscription Agreement.
